Bystander killing of tumour cells by antibody-targeted enzymatic activation of a glucuronide prodrug

被引:44
作者
Cheng, TL
Wei, SL
Chen, BM
Chern, JW
Wu, MF
Liu, PW
Roffler, SR [1 ]
机构
[1] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan
[2] Natl Def Med Ctr, Grad Inst Life Sci, Taipei 100, Taiwan
[3] Fu Jen Catholic Univ, Dept Biol, Hsin Chuang 242, Taiwan
[4] Natl Taiwan Univ, Sch Pharm, Taipei 100, Taiwan
[5] Natl Taiwan Univ, Coll Med, Taipei 100, Taiwan
关键词
bystander effect; antibody-directed enzyme prodrug therapy; monoclonal antibody; prodrugs; beta-glucuronidase; immunoconjugates;
D O I
10.1038/sj.bjc.6690221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
RHI-beta G-PEG, formed by linking poly(ethylene glycol)-modified beta-glucuronidase to Mab RH1, was employed to examine bystander killing of antigen-negative N1S1 rat hepatoma cells by activation of a glucuronide prodrug (BHAMG) of p-hydroxyaniline mustard (pHAM) at antigen-positive AS-30D rat hepatoma cells. Sequential treatment of cells with 10 mu g ml(-1) RH1-beta G-PEG and 20 mu M BHAMG was not toxic to N1S1 cells but killed 99% of AS-30D cells. Over 98% of N1S1 cells, however, were killed in mixed populations containing as few as 2% AS-30D cells after identical treatment, demonstrating an in vitro bystander effect. Subcutaneous injection of AS-SOD and N1S1 cells in BALB/c nu/nu mice produced solid tumours containing both cells. Uptake of radiolabelled RH1-beta G-PEG in solid AS-SOD and mixed AS-30D/N1S1 tumours was 11.6 and 9.3 times greater than a control antibody conjugate 120 h after i.v. injection, intravenous treatment with RH1-beta G-PEG and BHAMG cured seven of seven nude mice bearing solid s.c, AS-30D tumours and significantly delayed, compared with control conjugate and prodrug treatment, the growth of mixed N1S1/AS-30D tumours with one cure, showing that targeted activation of BHAMG kills bystander tumour cells in vivo.
引用
收藏
页码:1378 / 1385
页数:8
相关论文
共 23 条
  • [1] A CYTO-TOXIC AGENT CAN BE GENERATED SELECTIVELY AT CANCER SITES
    BAGSHAWE, KD
    SPRINGER, CJ
    SEARLE, F
    ANTONIW, P
    SHARMA, SK
    MELTON, RG
    SHERWOOD, RF
    [J]. BRITISH JOURNAL OF CANCER, 1988, 58 (06) : 700 - 703
  • [2] BAXTER LT, 1992, CANCER RES, V52, P5838
  • [3] CHARI RVJ, 1995, CANCER RES, V55, P4079
  • [4] Chen BM, 1997, INT J CANCER, V73, P392, DOI 10.1002/(SICI)1097-0215(19971104)73:3<392::AID-IJC14>3.3.CO
  • [5] 2-6
  • [6] Poly(ethylene glycol) modification of beta-glucuronidase-antibody conjugates for solid-tumor therapy by targeted activation of glucuronide prodrugs
    Cheng, TL
    Chen, BM
    Chan, LY
    Wu, PY
    Chern, JW
    Roffler, SR
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 1997, 44 (06) : 305 - 315
  • [7] DOUILLARD JY, 1986, CANCER RES, V46, P4221
  • [8] FUJIMORI K, 1990, J NUCL MED, V31, P1191
  • [9] MICROVASCULAR PERMEABILITY OF NORMAL AND NEOPLASTIC TISSUES
    GERLOWSKI, LE
    JAIN, RK
    [J]. MICROVASCULAR RESEARCH, 1986, 31 (03) : 288 - 305
  • [10] Jain R. K., 1990, CANCER RES S, V50, P814